Taysha Gene Therapies (TSHA) to Release Quarterly Earnings on Tuesday

Taysha Gene Therapies (NASDAQ:TSHA) is scheduled to post its quarterly earnings results after the market closes on Tuesday, May 14th. Analysts expect Taysha Gene Therapies to post earnings of ($0.11) per share for the quarter.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Tuesday, March 19th. The company reported $0.35 EPS for the quarter. The firm had revenue of $3.60 million during the quarter, compared to analyst estimates of $4.75 million. On average, analysts expect Taysha Gene Therapies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Taysha Gene Therapies Trading Down 4.0 %

Shares of TSHA opened at $2.38 on Wednesday. The firm’s fifty day moving average is $2.66 and its two-hundred day moving average is $2.10. The stock has a market cap of $445.11 million, a PE ratio of -3.70 and a beta of 0.37. The company has a quick ratio of 4.08, a current ratio of 4.08 and a debt-to-equity ratio of 0.54. Taysha Gene Therapies has a 52-week low of $0.50 and a 52-week high of $3.89.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Piper Sandler initiated coverage on Taysha Gene Therapies in a report on Tuesday, April 9th. They issued an “overweight” rating and a $9.00 price target for the company. Chardan Capital lifted their price objective on Taysha Gene Therapies from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, March 21st. Needham & Company LLC reiterated a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, May 2nd. Canaccord Genuity Group reiterated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, March 21st. Finally, JMP Securities reiterated a “market outperform” rating and set a $5.00 target price on shares of Taysha Gene Therapies in a research note on Wednesday, March 20th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $6.88.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.